Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background Evidence suggests that physiologic pacing (dual-chamber or atrial) may be
superior to single-chamber (ventricular) pacing because it is associated with lower risks of atrial …

Background One quarter of strokes are of unknown cause, and subclinical atrial fibrillation
may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid atrial …

Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy
protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. …

The Canadian Atrial Fibrillation Anticoagulation Study was a randomized double-blind
placebo-controlled trial to assess the potential of warfarin to reduce systemic thromboembolism …

Aims Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs
medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained …

Background Dronedarone restores sinus rhythm and reduces hospitalization or death in
intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic …

Background Dabigatran is an oral direct thrombin inhibitor that has been shown to be an
effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of …

Background—Patients surviving ventricular fibrillation (VF) or sustained ventricular
tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The implantable …